Mavacamten, a novel revolutionizing therapy in hypertrophic obstructive cardiomyopathy: A literature review-Reference-Cited by-同舟云学术

Mavacamten, a novel revolutionizing therapy in hypertrophic obstructive cardiomyopathy: A literature review

Published:2022-08 Issue:8 Volume:41 Page:693-703
ISSN:0870-2551
Container-title:Revista Portuguesa de Cardiologia
language:en
Short-container-title:Revista Portuguesa de Cardiologia

Author:

Aguiar Tiago^ORCID,Martins Elisabete

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference55 articles.

1. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC);Elliott;Eur Heart J,2014

2. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Ommen;Circulation,2020

3. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases;Elliott;Eur Heart J,2008

4. Prevalence of hypertrophic cardiomyopathy in a general population of young adults;Maron;Circulation,1995

5. Epidemiology of the inherited cardiomyopathies;McKenna;Nat Rev Cardiol,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mavacamten, a precision medicine for hypertrophic cardiomyopathy: From a motor protein to patients;Science Advances;2023-07-28

2. Mavacamten in obstructive hypertrophic cardiomyopathy: a profile of its use;Drugs & Therapy Perspectives;2023-06-22